Medicamen Organics MD, chairman, board of directors and AGM
NSE: MEDIORGPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹25.45.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹37 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 May 2026
- −13.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.50
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,000100.0% delivered
Medicamen Organics board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- N C RAJ & ASSOCIATESPeer-review certificate valid to Feb 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Medicamen Organics AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Medicamen Organics share news and announcements
Annual general meeting, 25 Sep 2026
460 shareholders on the register on 18 Sep 2026; present: 2 promoters and 12 others; votes counted by Divya Rani / M/s Divya Rani & Associates.The company's voting result (opens in a new tab)
To consider and adopt the Audited (Standalone and Consolidated) Financial Statements of the Company for the financial year ended on March 31, 2026, comprising of the Balance Sheet as at March 31, 2026, Statement of Profit & Loss for the year ended on that date, Cash Flow Statement and Statement of changes in Equity for the financial year ended on March 31, 2026, along with the explanatory notes annexed thereto and forming part of the aforesaid documents and the reports of the Board of Directors and the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 60.04% · promoters 100.00% · institutions 0.00% · other public 11.43%
- To re-appoint Mr. Ashutosh Gupta (DIN: 00039995), who retires by rotation, and, being eligible, offers himself for re-appointment as Director.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 60.04% · promoters 100.00% · institutions 0.00% · other public 11.43%
- To approve the re-appointment of Secretarial Auditors of the Company for the financial year 2026-27Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 60.04% · promoters 100.00% · institutions 0.00% · other public 11.43%
- To approve material related party transactions with Grande Etoile Pharmaceuticals Limited, Subsidiary and Related Party of the Company.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 5.15% · promoters 0.00% · institutions 0.00% · other public 11.43%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 9 Apr 2026, 5 resolutions
540 shareholders on the register on 1 Apr 2026; present: 2 promoters and 3 others; votes counted by ANU MALOHTRA / ANU MALOHTRA & ASSOCIATES.The company's voting result (opens in a new tab)
- Approval For Increase Of Authorised Share Capital Of The Company And Consequent Alteration Of Capital Clause Of Memorandum Of Association Of The Company.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 65.20% · promoters 100.00% · institutions 0.00% · other public 14.19%
- Approval For The Appointment Of Mr. Pankaj Tiwari (Din: 11565750) As An Executive Director Of The CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 65.20% · promoters 100.00% · institutions 0.00% · other public 14.19%
- Preferential Issuance Of Upto 20,00,000 (Twenty Lakhs Only) Equity Shares To The Person Belonging To Non-Promoter, Public Category.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 65.20% · promoters 100.00% · institutions 0.00% · other public 14.19%
- Issuance Of 11,85,715 Fully Convertible Warrants (“Warrants”) To The Persons Belonging To “Promoter” And “Non-Promoter (Public Category)” Category On Preferential Basis.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 65.20% · promoters 100.00% · institutions 0.00% · other public 14.19%
- Approval For Conversion Of Loan Into 7,14,285 Equity Shares Of The Company On Preferential Basis To The Persons Belonging To Promoter Category.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 65.20% · promoters 100.00% · institutions 0.00% · other public 14.19%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Spent elsewhere, amount | Reason and comments |
|---|---|---|---|---|---|---|---|
| Public IssuesJun 2024 | 10.54 | Yes | 1.62 | 1.38 | Yes | 1.62 | Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusMoreLessAudit committee: Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.MoreLess |
| Public IssuesJun 2024 | 10.54 | Plant updation and increase in production capacity | 2.25 | 2.25 | Yes | Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusMoreLessAudit committee: Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.MoreLess | |
| Public IssuesJun 2024 | 10.54 | Funding working capital requirements of our Company | 4.00 | 5.62 | Yes | Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusMoreLessAudit committee: Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.MoreLess | |
| Public IssuesJun 2024 | 10.54 | General corporate purpose | 0.39 | 0.39 | Yes | Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusMoreLessAudit committee: Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.MoreLess | |
| Public IssuesJun 2024 | 10.54 | Issue Related Expenses | 0.90 | 0.90 | Yes | Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectusMoreLessAudit committee: Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.MoreLess | |
| Preferential IssuesMar 2025 | 3.00 | Working capital requirements and General corporate purpose | 3.00 | 3.00 | No |